Medexus to Participate in the 34th Annual Roth Conference

2 years ago

TORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF)…

Dyve Biosciences to Present at the 34th Annual Roth Conference

2 years ago

CAMARILLO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal…

Noah Medical Announces New Research and Training Facilities for Next Generation Medical Robotics Platforms

2 years ago

SAN CARLOS, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today unveiled a new 10,000 square…

Running for Research – Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome

2 years ago

REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results

2 years ago

FLORHAM PARK, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel…

Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

2 years ago

WORCESTER, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on…

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

2 years ago

WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to…

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

2 years ago

WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that…

P3 Health Partners Announces Select Preliminary Fourth Quarter and Full Year 2021 Results, and Introduces 2022 Outlook

2 years ago

Strong revenue growth of 46% for the fourth quarter and 32% for full year 2021 Full year 2022 revenue expected…

Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV:PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)

2 years ago

SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a…